Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin ($BMRN). Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation ($MDVN) for $410 million up front, with another $160 million in milestones. The prospect--talazoparib--entered Phase III back in 2013 for advanced breast cancer among patients with BRCA 1 or BRCA 2 mutations, and Medivation is hoping to add it to a marketed portfolio that already includes the successful prostate cancer pill Xtandi. More

Suggested Articles

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.

AstraZeneca partners with actor and asthma sufferer Tony Hale to raise awareness about eosinophilic asthma and blood testing to diagnose it.

Even at its maximum, Roche's oral Evrysdi comes at a discount to Spinraza's low-end, maintenance list price.